Everything below concerns Selank. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues; tuftsin plus a Pro-Gly-Pro tail |
| Molecular formula | C33H57N11O9 | Commonly reported value for the free peptide |
| Monoisotopic mass | Roughly 751.4 Da | Average molecular mass near 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Freely soluble in water | Also dissolves in saline and other polar solvents |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
The dye substance is a mucous secretion from the hypobranchial gland of one of several species of medium-sized predatory sea snails that are found in the eastern Mediterranean Sea, and off the Atlantic coast of Morocco. David Jacoby remarks that "twelve thousand snails of Murex brandaris yield no more than 1.4 grams (22 grains) of pure dye, enough to colour only the trim of a single garment." These are the marine gastropods Bolinus brandaris the spiny dye-murex (originally known as Murex brandaris Linnaeus, 1758), the banded dye-murex Hexaplex trunculus, the rock-shell Stramonita haemastoma, and less commonly a number of other species such as Bolinus cornutus. The dye is an organic compound of bromine (i.e., an organobromine compound), a class of compounds often found in algae and in some other sea life, but much more rarely found in the biology of land animals. This dye is in contrast to the imitation purple that was commonly produced using cheaper materials than the dyes from the sea snail. In nature, the snails use the secretion as part of their predatory behaviour to sedate prey and as an antimicrobial lining on egg masses. The snail also secretes this substance when it is attacked by predators, or physically antagonized by humans (e.g., poked). Therefore, the dye can be collected either by "milking" the snails, which is more labor-intensive but is a renewable resource, or by collecting and destructively crushing the snails. The dye is collected via the snail-harvesting process, involving the extraction of the hypobranchial gland (located under the mollusk's mantle).
==== Psychotherapy ==== Psychotherapy for individuals with AN is challenging as they may value being thin and may seek to maintain control and resist change. Initially, developing a desire to change is fundamental. There is no strong evidence to suggest one type of psychotherapy over another for treating anorexia nervosa in adults or adolescents.
Southern Association, previously Class A1 (1936–1945) Texas League, previously Class A1 (1936–1942; idle for three seasons during World War II) The Texas League remained in Double-A for the next 75 years. During this time, there were limited changes to leagues at the Double-A level:
Sources: en.wikipedia.org
This led Santa Fe Opera to add one more performance. As well, Santa Fe Opera secured an agreement with the Dutch recording label Pentatone to produce a commercial recording of the opera, captured live from the Santa Fe Opera production. The director of the premiere production at Santa Fe Opera was Leonard Foglia, with set design by Robert Brill, lighting design by Brian Nason, costumes by David C. Woolard and projection design by Elaine J. McCarthy. Miguel Harth-Bedoya was the conductor. With respect to Opera Philadelphia, Cold Mountain is part of the company's "American Repertoire Program", a ten-year commitment to produce a contemporary American work each season. For the second production of Cold Mountain, at Opera Philadelphia, Higdon and Scheer made modest revisions. In late January 2016, Nathan Gunn withdrew from the Opera Philadelphia production because of a family medical emergency. Jarrett Ott, the understudy for Inman in both the Santa Fe Opera and Opera Philadelphia rosters, stepped into the role of Inman for the Opera Philadelphia performances. The Pentatone commercial recording of Cold Mountain was released in April 2016. It received two Grammy nominations.[1] In May 2016, Cold Mountain was the winner in the category of World Premiere at the International Opera Awards in London. In July 2019, Cold Mountain made its West Coast Premiere at the Music Academy of the West 2019 Summer Festival.
==== Removing excess coolant ==== After the area to be branded is cleaned and soaked with alcohol, the brand is removed from its coolant. It is very important to shake the brand vigorously to remove as much coolant as possible from its working surface. This is necessary because drips of coolant are capable of freezing an animal's skin on their own as they roll down its body, producing a permanent drip mark down the hide of the animal. It is also necessary because the dynamic viscosity of ethanol greatly increases at cryogenic temperatures, rising more than eight-fold from room temperatures. The thicker alcohol necessitates a more thorough shaking than one would give the same brand covered in water.
=== Special populations === Pregnancy: studies in lab animals showed no harm to the baby. However, a comparable well-controlled study has not been performed in pregnant women. Nursing: breast milk has been shown to contain small amounts of labetalol (0.004% original dose). Prescribers should be cautious in the use of labetalol for nursing mothers. Pediatric: no studies have established safety or usefulness in this population. Geriatric: Due to an increased likelihood of experiencing orthostatic symptoms such as dizziness, product labelling recommends that elderly patients receive counselling regarding these side effects during labetalol treatment. Furthermore, because drug elimination is reduced in older demographics, lower maintenance doses are typically sufficient to achieve therapeutic effects.
Sources: en.wikipedia.org
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.
No peptide with this exact sequence has been identified as an endogenous substance. It is a laboratory-designed analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The Pro-Gly-Pro extension has no known natural source.
Proline introduces conformational constraints that make a peptide less accessible to common peptidases. This is a standard stabilization strategy in peptide design. The added residues also increase the distance between the active tuftsin portion and typical cleavage sites.
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.